ArticleJournal of translational medicine2025
Do cancer survivors have an increased risk of developing subsequent cancer? A population-based study.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial.Nature medicine · 2026Trial
- Risk of developing subsequent primary breast cancer among non-breast cancer survivors: a retrospective cohort study.Breast cancer (Tokyo, Japan) · 2026Article
- Subsequent malignant neoplasm among cancer survivors in the United States.Journal of cancer survivorship : research and practice · 2026Article
- The prevalence of primary lung cancer among women with previous personal and/or family history of cancer in an integrated health system.JTCVS open · 2026Article
- Impact of Multicancer Screening on Late-Stage Cancer at Diagnosis in Breast Cancer Survivors: A Modeling Study.JCO precision oncology · 2026Article
- Imperatorin: A Furanocoumarin with Potential in Combating Cancer Development and Progression-A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Favorable survival of patients with nasopharyngeal carcinoma associated with metachronous multiple primary cancers: A retrospective study.Oncology letters · 2025Article
- Swinging Mass Through the Pulmonary Valve: A Rare Case of Right Ventricular Myxoma.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe number of cancer survivors has steadily increased due to earlier detection and more effective therapies. Do all types of cancer survivors have an increased risk of developing subsequent cancers compared with the general population?
methodsPatients diagnosed with malignant cancer between January 2000 and December 2021 were included from the SEER 17 Registries (excl AK) database. Events were defined as subsequent cancer at any site according to ICD-O-3/WHO 2008. The observed and expected numbers of subsequent cancers were retrieved, and observed/expected (O/E) ratios and excess risks were calculated to assess the risk of developing subsequent cancers in cancer survivors compared with the United States general population within the same period. We obtained standard incidence ratios for the entire cohort and stratified the data by demographics, treatment, and cancer type.
resultsOur findings indicate that compared with the general population, cancer survivors have a 16% greater risk of developing subsequent cancers (p < 0.05). All the subgroups also presented a significantly greater risk of developing subsequent cancers, even after stratification by demographics, treatment, and historic stage. Male patients with prostate cancer had a 31% lower risk of developing subsequent cancers, whereas female patients with lung and bronchus cancer presented a 93% increased risk.
conclusionOur findings suggest that nearly all groups of cancer survivors experienced a significantly increased risk of developing subsequent cancers, whereas men with prostate cancer presented a 31% lower risk. These differential risks provide clinicians with evidence-based suggestions for tailored surveillance and prevention strategies. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.